Epidermal growth factor receptor (EGFR)-directed PROTACs: mechanistic validation, mutant selectivity, and translational challenges.

Hegde Y, Mehta RK, Tan M, Lawrence TS, Bridges AJ, Nyati MK

Open source

DOI
10.1080/17460441.2026.2736536
Published
2026 Sep 20
Container
Expert opinion on drug discovery
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17460441.2026.2736536,
  title = {Epidermal growth factor receptor (EGFR)-directed PROTACs: mechanistic validation, mutant selectivity, and translational challenges.},
  author = {Hegde Y and Mehta RK and Tan M and Lawrence TS and Bridges AJ and Nyati MK},
  year = {2026},
  journal = {Expert opinion on drug discovery},
  doi = {10.1080/17460441.2026.2736536},
  url = {https://doi.org/10.1080/17460441.2026.2736536}
}

RIS

TY  - JOUR
TI  - Epidermal growth factor receptor (EGFR)-directed PROTACs: mechanistic validation, mutant selectivity, and translational challenges.
AU  - Hegde Y
AU  - Mehta RK
AU  - Tan M
AU  - Lawrence TS
AU  - Bridges AJ
AU  - Nyati MK
PY  - 2026
JO  - Expert opinion on drug discovery
DO  - 10.1080/17460441.2026.2736536
UR  - https://doi.org/10.1080/17460441.2026.2736536
ER  - 

APA

Y, H., RK, M., M, T., TS, L., AJ, B., & MK, N. (2026). Epidermal growth factor receptor (EGFR)-directed PROTACs: mechanistic validation, mutant selectivity, and translational challenges.. Expert opinion on drug discovery. https://doi.org/10.1080/17460441.2026.2736536

Source records